Company intelligence / Profile preview

CORAT Therapeutics GmbH

Braunschweig, Lower Saxony, Germanycorat-therapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

COR-101, their lead antibody, demonstrated high efficacy in hamster disease models, showing recovery within two days compared to a week for untreated animals. The antibody binds and inhibits all B.1.617 SARS-CoV-2 variants, including the "delta" variant.

Therapeutic areas: Infectious Diseases
Modalities: AntibodiesHuman neutralizing antibodies
Industry: Biotech

Drug pipeline

1 asset

COR-101

Partnerships

Dermapharm Holding SE

Beyond the preview

Go deeper on CORAT Therapeutics GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CORAT Therapeutics GmbH.